

Haematologica
HAEMATOL/2017/169656
Version 3

Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients
with relapsed and refractory non-Hodgkin lymphoma

Anas Younes, Gilles Salles, Giovanni Martinelli, Robert Gregory
Bociek, Dolores Caballero Barrigon, Eva González Barca, Mehmet
Turgut, John Gerecitano, Oliver Kong, Chaitali Babanrao Pisal,
Ranjana Tavorath, and Won Seog Kim

Disclosures: Anas Younes: Received honoraria from Novartis, Gilead, and Infinity Gilles Salles: Reports personal fees from novartis, during the conduct of the study; personal fees from amgen, personal fees from mundipharma, personal fees from gilead, personal fees from janssen, personal fees from novartis, grants, personal fees and non-financial support from Roche, personal fees from celgene, outside the submitted work. Giovanni Martinelli: Nothing to disclose. R. Gregory Bociek: Nothing to disclose. Dolores Caballero Barrigon: Nothing to disclose. Eva Maria González Barca: Nothing to disclose. Mehmet Turgut: Nothing to disclose. John Gerecitano: Nothing to disclose. Oliver Kong: Novartis employee and owns a Novartis stock Chaitali Babanrao Pisal: Novartis employee Ranjana Tavorath: Novartis employee Won Seog Kim: Research fund received from Roche, Takeda, Kyowa-Kirin, Novartis, Celltrion, Janssen, Pfizer, Mundipharma

Contributions: Contributions: The sponsor (Novartis Pharmaceuticals) and the study steering committee (A.Y., G.S., and W.S.K.) designed the study. The data was collected and analyzed by the sponsor in conjunction with the authors, who had full access to the data and can attest to the accuracy and integrity of the data. A.Y. and W.S.K. wrote the manuscript with medical editorial support from ArticulateScience LLC, which was funded by the sponsor. All authors contributed to draft revisions and approved the final version of the manuscript. Conflict-of-interest disclosure: The study was funded by Novartis Pharmaceuticals; O.K., C.B.P., and R.T. are employees of Novartis. A.Y. received honoraria from Gilead, Infinity, and Novartis. GS received honoraria from Amgen, Celgene, Gilead, Janssen, Mundipharma, Novartis, and Roche, as well as grants and non-financial support from Roche. W.S.K. received research funding from Celltrion Healthcare, Janssen, Kyowa-Kirin, Mundipharma, Novartis, Pfizer, Roche, and Takeda. The remaining authors declare no competing interests.